Ruolin Li

Dr. Ruolin Li

Department of Internal Medicine, Erasmus MC, Rotterdam, Zuid-Holland, The Netherlands
+1
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2023 in Genes
Verified
Journal Article
Open access
PDF file
RLRuolin Li
Ruolin Li
FSFereshteh Shokri
Fereshteh Shokri
ALAlejandro Lopez-Rincon
Alejandro Lopez-Rincon
FRFernando Rivadeneira
Fernando Rivadeneira
CGCarolina Medina Gomez
Carolina Medina Gomez
Fariba AhmadizarFariba Ahmadizar
Fariba Ahmadizar
Background: Although common drugs for treating type 2 diabetes (T2D) are widely used, their therapeutic effects vary greatly. The interaction between the gut microbiome and glucose-lowering drugs is one of the main contributors to the variability in T2D progression and response to therapy. On the one hand, glucose-lowering drugs can alter gut microbiome components. On the other hand, specific gut microbiota can influence glycemic control as the therapeutic effects of these drugs. Therefore, this systematic review assesses the bi-directional relationships between common glucose-lowering drugs and gut microbiome profiles. Methods: A systematic search of Embase, Web of Science, PubMed, and Google Scholar databases was performed. Observational studies and randomised controlled trials (RCTs), published from inception to July 2023, comprising T2D patients and investigating bi-directional interactions between glucose-lowering drugs and gut microbiome, were included. Results: Summarised findings indicated that glucose-lowering drugs could increase metabolic-healthy promoting taxa (e.g., Bifidobacterium) and decrease harmful taxa (e.g., Bacteroides and Intestinibacter). Our findings also showed a significantly different abundance of gut microbiome taxa (e.g., Enterococcus faecium (i.e., E. faecium)) in T2D patients with poor compared to optimal glycemic control. Conclusions: This review provides evidence for glucose-lowering drug and gut microbiome interactions, highlighting the potential of gut microbiome modulators as co-adjuvants for T2D treatment.

27 December 2024 in The Lancet Regional Health - Europe
Verified
Journal Article
Open access
RLRuolin Li
Ruolin Li
AKAlexander Kurilshikov
Alexander Kurilshikov
SYShuyue Yang
Shuyue Yang
JOJulie A.E. van Oortmerssen
Julie A.E. van Oortmerssen
AHArno van Hilten
Arno van Hilten
CGCarolina Medina Gomez
Carolina Medina Gomez
The human gut microbiome changes considerably over time. Previous studies have shown that gut microbiome profiles correlate with multiple metabolic traits. As disease development is likely a lifelong process, evidence gathered at different life stages would help gain a better understanding of this correlation. Therefore, we aim to investigate how the association of the gut microbiome and metabolic traits change over the lifespan. We identified microbiome patterns (clusters) within two population-based cohorts at different life stages, i.e., pre-adolescents of the Generation R Study (mean age 9.8 years; n = 1488) and older adults of the Rotterdam Study (RS, mean age 62.7 years; n = 1265) using K-Means clustering, and surveyed for host metabolic phenotypes, lifestyles and other factors driving these patterns. Analyses were replicated in the Lifelines-DEEP Study (mean age 45.0 years; n = 1117). The association between microbiome clusters and host metabolic health was evaluated as well as the link between microbiome clusters and incident atherosclerotic cardiovascular disease (ASCVD) in RS during follow-up (median 6.5 years). We identified two distinct microbiome clusters (U and H) within each study population presenting contrasting metabolic statuses. Cluster U was characterized by lower microbiome diversity, increased Streptococcus, Fusicatenibacter, and decreased Prevotella_9 and Christensenellaceae_R-7_group; wherein individuals showed higher fat percentage, triglycerides, use of medications, and lower socioeconomic status. Individuals in cluster U had increased odds (between 1.10 and 1.65) of being relatively metabolically unhealthy and presented a higher 5-year ASCVD risk (mean risk 0.059 ± 0.071 vs 0.047 ± 0.042, p < 0.001). We provide evidence of a life–course relationship between gut microbiome profiles and metabolic health. R.L is supported by 10.13039/501100000780 European Union 10.13039/501100007601 Horizon 2020 research and innovation program under Marie Skłodowska-Curie grant agreement No 860898 [FIDELIO].

21 February 2025 in medRxiv
Verified
Preprint
Open access
PDF file
RLRuolin Li
Ruolin Li
POPaul C. Okoro
Paul C. Okoro
MZM. Carola Zillikens
M. Carola Zillikens
RVRamachandran S. Vasan
Ramachandran S. Vasan
SSShivani Sahni
Shivani Sahni
CGCarolina Medina Gomez
Carolina Medina Gomez
Background: Bones and muscles are connected anatomically, and functionally. Preliminary evidence has shown the gut microbiome influences the aging process of bone and muscle in animal studies. However, such evidence in humans is still scarce. This study aimed to assess the microbiome-bone and microbiome-muscle associations in two cohorts of community-dwelling older adults. Methods: We leveraged information from two large population-based cohorts, i.e., the Rotterdam Study (mean age 62.7 ± 5.6 years; n=1,249) and the Framingham Heart Study (mean age 55.2 ± 9.1 years; n=1,227). For individuals included in this study, gut microbiome 16S rRNA sequencing, musculoskeletal phenotyping derived from DXA images, lifestyle and socioeconomic data, and medication records were available. Per cohort, the 16S rRNA sequencing data, derived from stool, were processed with the DADA2 pipeline and taxonomies were assigned using the SILVA reference database. In addition, the microbiome functional potential was obtained with PICRUSt2. Further, we investigated the association between the human gut microbiome (alpha diversity, genera and predicted functional pathways) and appendicular lean mass (ALM), femoral neck bone mineral density (FN-BMD) and trabecular bone score (TBS) using multilinear regression models controlling for multiple confounders, and performed a joint analysis from both cohorts. Sex-stratified analyses were also conducted. Results: The gut microbiome alpha diversity was not associated with either tested phenotype after accounting for multiple-testing (P>1.67e-02). In the joint analysis, lower abundance of Oscillibacter (beta= −.51, 95%CI [−0.74, −.29]), Anaerotruncus (beta=-0.41, 95%CI [−0.61, - 0.21]), Eisenbergiella (beta=-0.39, 95%CI [−0.59, −.19]) and higher abundance of Agathobacter (beta=0.40, 95%CI [0.20, 0.60]) were associated with higher ALM (P<2.0e-04). Lower abundance of Anaerotruncus (beta=-0.32, 95%CI [−0.45, −.19]), Hungatella (beta=-0.26, 95%CI [−0.38, −.15]) and Clostridiales bacterium DTU089 (beta=-0.37, 95%CI [−0.55, −.19]) was associated with higher ALM only in females (P< 2.0e-04). Moreover, the biotin biosynthesis II pathway was positively associated with ALM (beta=0.44, 95% CI [0.24, 0.64]) (P<1.90e-04) in females while no associations were observed in males. We did not observe any robust association of bone traits with gut microbiome features. Conclusion: Our results indicate that specific genera are associated with ALM in middle-aged and older adults and these associations can present in a sex-specific manner. Overall, our study suggests that the gut microbiome is linked to muscle aging in middle-aged and older adults. However, larger sample sizes are still needed to underpin the specific microbiome features involved.

22 January 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
RLRuolin Li
Ruolin Li
JVJoost A.M. Verlouw
Joost A.M. Verlouw
CBCindy G. Boer
Cindy G. Boer
PAPascal Arp
Pascal Arp
JMJoyce van Meurs
Joyce van Meurs
CGCarolina Medina Gomez
Carolina Medina Gomez
: The widespread application of high-throughput Next Generation Sequencing (NGS) technologies has made microbiome research an emerging field in public health and biomedical sciences. However, there are still many challenges that need to be addressed in this field. Pipelines available to generate microbiome data across cohorts are diverse, and sources of variation to be recorded and evaluated during microbiome profiling have not been standardized. Moreover, meticulous quality control of the microbiome data processing, from collection to computational quantification is still challenging, especially in large population studies. Innovative approaches are required to handle samples and to minimize the potential bias introduced by logistic hurdles in biobanking. In this paper, we describe the methodological steps surrounding the optimization of the 16s rRNA gut microbiome profiling in two large prospective cohorts the Generation R Study (mean age 9.83 ± 0.32 years) and the Rotterdam Study (mean age 62.67 ± 5.66 years). This paper also highlights potential solutions to sample mislabeling in large-scale microbiome analysis. To summarize, our study addresses common problems in human microbiome research. It aims to improve the research quality and reliability by integrating more stringent quality control standards into microbiome research.